Central nervous system therapy for lysosomal storage disorders
- PMID: 18341388
- DOI: 10.3171/FOC/2008/24/3-4/E11
Central nervous system therapy for lysosomal storage disorders
Abstract
Most lysosomal storage disorders are characterized by progressive central nervous system impairment, with or without systemic involvement. Affected individuals have an array of symptoms related to brain dysfunction, the most devastating of which is neurodegeneration following a period of normal development. The blood-brain barrier has represented a significant impediment to developing therapeutic approaches to treat brain disease, but novel approaches-including enzyme replacement, small-molecule, gene, and cell-based therapies-have given children afflicted by these conditions and those who care for them hope for the future.
Similar articles
-
Molecular pathologies of and enzyme replacement therapies for lysosomal diseases.CNS Neurol Disord Drug Targets. 2006 Aug;5(4):401-13. doi: 10.2174/187152706777950738. CNS Neurol Disord Drug Targets. 2006. PMID: 16918392 Review.
-
Bone marrow transplantation in young aspartylglucosaminuria mice: improved clearance of lysosomal storage in brain by using wild type as compared to heterozygote donors.Bone Marrow Transplant. 2004 Dec;34(11):1001-3. doi: 10.1038/sj.bmt.1704665. Bone Marrow Transplant. 2004. PMID: 15489878 No abstract available.
-
Neuronopathic lysosomal storage disorders: Approaches to treat the central nervous system.Best Pract Res Clin Endocrinol Metab. 2015 Mar;29(2):159-71. doi: 10.1016/j.beem.2014.12.001. Epub 2015 Jan 5. Best Pract Res Clin Endocrinol Metab. 2015. PMID: 25987170 Review.
-
Addressing neurodegeneration in lysosomal storage disorders: Advances in Niemann Pick diseases.Neuropharmacology. 2020 Jul;171:107851. doi: 10.1016/j.neuropharm.2019.107851. Epub 2019 Nov 14. Neuropharmacology. 2020. PMID: 31734384 Review.
-
New therapeutic options for lysosomal storage disorders: enzyme replacement, small molecules and gene therapy.Hum Genet. 2007 Mar;121(1):1-22. doi: 10.1007/s00439-006-0280-4. Epub 2006 Nov 7. Hum Genet. 2007. PMID: 17089160 Review.
Cited by
-
Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.J Clin Invest. 2013 Aug 1;123(8):3254-3271. doi: 10.1172/JCI66778. Epub 2013 Jul 1. J Clin Invest. 2013. PMID: 23863627 Free PMC article.
-
Hematopoietic Stem Cell Transplantation for Neurological Disorders: A Focus on Inborn Errors of Metabolism.Front Cell Neurosci. 2022 May 26;16:895511. doi: 10.3389/fncel.2022.895511. eCollection 2022. Front Cell Neurosci. 2022. PMID: 35693884 Free PMC article. Review.
-
Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice.Mol Ther. 2012 Feb;20(2):254-66. doi: 10.1038/mt.2011.220. Epub 2011 Oct 18. Mol Ther. 2012. PMID: 22008915 Free PMC article.
-
Seven-year follow-up of durability and safety of AAV CNS gene therapy for a lysosomal storage disorder in a large animal.Mol Ther Methods Clin Dev. 2021 Oct 5;23:370-389. doi: 10.1016/j.omtm.2021.09.017. eCollection 2021 Dec 10. Mol Ther Methods Clin Dev. 2021. PMID: 34761052 Free PMC article.
-
Stem Cells in Neurological Disorders: Emerging Therapy with Stunning Hopes.Mol Neurobiol. 2015 Aug;52(1):610-25. doi: 10.1007/s12035-014-8883-6. Epub 2014 Sep 23. Mol Neurobiol. 2015. PMID: 25241647 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources